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ABSTRACT
Purpose: Patients with diagnosis of hormone-refractory prostate cancers (HRPC) present a very het-
erogeneous population, and therefore it has been proposed to sub-categorize them into two sub-
groups depending on presence or absence of distant metastases. While the former subgroup has been 
typically treated with palliative intention, for the latter apparently there is no standard approach. The 
role of three-dimensional conformal radiotherapy (3D-CRT) for this subgroup has not been well docu-
mented in the literature. Thus, the purpose of this work is to analyze the results of treatment of non-
metastatic androgen-refractory prostate cancer (ARPC) with 3D-CRT and to investigate the potential 
prognostic factors which infl uenced the results.  
MATERIAL AND METHODS: Of 424 patients with diagnosis of localized and locally advanced prostate 
cancer who were treated between 1999 and 2004 in our centre, forty-three (n=43) patients were 
classifi ed as non-metastatic ARPC. Distant metastases were excluded by negative bone scan, negative 
chest X-ray and negative pelvic CT for lymph node metastases. The median pre-hormone therapy PSA 
(pre-HT PSA) level for this group was 24 ng/ml (range 1 to 120) and 5.7 ng/ml (range 0.06 to 27) at the 
beginning of radiotherapy (pre-RT PSA). Clinical T stage distribution, defi ned according to the 2002 
AJCC, was as follows: T1c = 12, T2 = 23, and T3 = 8 patients, respectively. Of 44 patients, 39 had a 
Gleason score of 2-7 and 4 had a Gleason score of 8 -10. All patients with diagnosis of non-metastatic 
ARPC were treated with 3D-CRT with the daily fraction dose of 2 Gy to a median total dose of 68 Gy 
(range from 60 to 74 Gy). The median duration of androgen ablation therapy before RT was 26 months 
(range from 7 to 96). The median time of follow-up after 3D-CRT was 27 months (range from 13 to 
62) and from the beginning of androgen ablation was 53 months (range from 20 to 158). The follow-
ing prognostic factors were evaluated in univariate and multivariate analysis: age, pre-HT PSA, pre-RT 
PSA, Gleason score, total dose, PSA doubling time (PSADT< 6 months vs. PSADT > 6 months).
RESULTS: The 5-year actuarial overall survival was 82% and 5-year clinical relapse free-survival rate 
was 49%. During the follow-up 14 patients developed disease progression (locoregional and/or dis-
tant and/or biochemical) and two patients died of prostate cancer. The univariate analysis indicated 
that pre-HT PSA > 20 ng/ml, pre-RT PSA > 4ng/ml, and the high-risk group defi ned according to 
NCCN criteria (PSA >20 ng/ml and Gleason score >7) were statistically signifi cant factors for the risk 
of disease progression. 
CONCLUSIONS: Three-dimensional conformal radiotherapy for patients with non-metastatic ARPC is 
a valuable method of treatment for the subgroup of patients with pre-HT PSA<20 ng/ml and Gleason 
score < 8. For patients classifi ed as the high-risk group according to NCCN criteria 3D-CRT seems to be 
an ineffective treatment due to the observed high incidence of distant failure, and should be viewed 
as costly and sophisticated yet ineffective intervention. For this subgroup a systemic modality of treat-
ment such as chemotherapy or biological manipulation should be considered.
KEY WORDS: non-metastatic hormone-refractory prostate cancer, three-dimensional confor-
mal radiotherapy, prognostic factors
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INTRODUCTION
Optimal treatment of prostate cancer is a fi eld 
of debate as a result of lack of outcomes of ran-
domized clinical trials which would compare 
the effi cacy of main treatment modalities such 
as radical prostatectomy, radiotherapy (exter-
nal beam therapy, brachytherapy), and hor-
monal therapy (HT) [1]. Hormonal therapy, 
the third main method of treatment, is used 
for prostate cancer treatment throughout a 
wide range of disease presentations because 
of the dependence of prostate cancer on tes-
tosterone [2]. In Poland, many patients are 
diagnosed in an advanced stage of disease, 
and thus androgen deprivation therapy (ADT) 
has frequently been used as the fi rst line of 
treatment by urologists [3]. Beside that, in 
some cases of localized stage of disease, treat-
ment is started with ADT as well. The main 
indication for HT in the latter group of pa-
tients is lack of the patient’s agreement for 
active methods of treatment such as surgery 
or radiotherapy. During hormonal treatment 
increase of serum PSA level only and/or lo-
cal progression without clinical evidence of 
distant progression in many cases changes 
the patient’s decision and gives permission 
to move on to more radical treatment such as 
radiotherapy. Generally, for patients classifi ed 
as nonmetastatic androgen-independent pros-
tate cancer (ARPC) prognosis is poor, with a 
median survival of approximately 20 months 
[4]. However, if in this group of patients we 
could distinguish two main subgroups - the 
fi rst with occult distant metastases and/or lo-
cal failure, and the second with local failure 
alone which is represented by biochemical re-
lapse too - then for the latter group an effi cient 
local therapy might have been strongly indi-
cated and effective. Therefore, selecting the 
subgroup of patients for whom radiotherapy 
could be benefi cial is a crucial point of treat-
ment of patients classifi ed as ARPC. The role 
of radiotherapy in the treatment of prostate 
cancer is well established, although the role 
of this method of treatment for patients with 
non-metastatic ARPC is not well documented 
[5]. To date, only a few studies have described 
the outcome of radiotherapy in hormone-re-
fractory prostate cancer [6–8]. Moreover, in 
the aforementioned studies important differ-
ences in patient selection and dose fraction-
ation existed.
The aim of this study was to analyze the 
results of treatment of non-metastatic ARPC 
with conventionally fractionated 3D CRT and 
to investigate the potential prognostic factors 
which infl uenced the results.
  
MATERIAL AND METHODS
Patient characteristics
Between May 1999 and December 2004, at 
the Great Poland Cancer Centre in Poznañ, 
424 patients with diagnosis of prostate cancer 
(T1-T3N0M0) were treated with three-dimen-
sional conformal radiotherapy (3D CRT) with 
curative intent. In the present study from this 
cohort only forty-three patients 43 (n=43) 
were included due to fulfi lment of the criteria 
for non-metastatic ARPC .    
The median age of patients was 71 years 
(range 55–79 years). Distribution of T stage 
was as follows: (T1c = 12, T2 = 23 patients, 
T3a = 8 patients). All patients had a pathologi-
cally confi rmed diagnosis of adenocarcinoma, 
which was classifi ed according to the Gleason 
scoring system. The average level of PSA be-
fore the beginning of HT (pre-HT PSA) was 
25 ng/ml (range 1 to 120 ng/ml) and the av-
erage PSA prior to RT (pre-RT PSA) was 5.7 
ng/ml (range 0.06 to 27 ng/ml).  
Before starting HT the following initial 
evaluation of disease was performed: digital 
rectal examination (DRE), transrectal ultra-
sonography (TRUS), bone scan, pelvis CT, 
chest X-ray. During hormonal therapy at 3-
month intervals DRE was performed and se-
rum PSA level measured. 
All patients referred for RT were restaged 
using the following examinations: physical 
examination with DRE, bone scan/skeletal X-
ray, chest X-ray, PSA serum level. In addition 
all patients had pelvic lymph nodes evaluated 
by computer tomography (CT) or magnetic 
resonance imaging (MRI) or ultrasound (US). 
None of the patients had diagnostic lymphade-
nectomy of the pelvic lymph nodes performed. 
Additionally all patients prior to HT and then 
before RT had a complete blood count, bio-
chemistry including serum BUN, creatinine, 
and liver enzymes.
Hormonal therapy
In the analyzed group of patients, the decision 
concerning HT was made before consultation 
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with a radiotherapist, which is unfortunately 
common in our community and therefore has 
not always been based on strict criteria derived 
from evidence-based medicine. For these pa-
tients treatment was started with antiandro-
gen (fl utamide) for a minimum of 2 weeks and 
then LHRH agonists were introduced. After 
a few weeks of therapy, the LHRH agonists 
alone were continued. In cases where the PSA 
level increased in 3 consecutive evaluations 
with 2-week intervals between measurements, 
the patient was classifi ed as having androgen-
refractory prostate cancer (ARPC). In such a 
clinical scenario the patient was referred for 
radiotherapy. All patients during and after the 
end of the radiotherapy course were treated 
with LHRH. During the follow-up additional 
hormonal manipulation was performed with 
the maximal androgen blockade (MAB) when 
antiandrogen was added. No other forms of 
second lines of ARPC were performed in the 
analyzed group. For all patients hormonal 
therapy was continued to the end of life.
Radiotherapy technique 
Simulation and treatment were performed 
in a supine position with “comfortable” full 
bladder. All patients had CT scanning of the 
pelvis in the treatment position (supine posi-
tion) at 5 mm increments across the treatment 
fi eld. Radiotherapy was administered using 20 
MV photons in a daily fraction of 1.8 Gy – 2.0 
Gy to a total median dose of 70.4 Gy (range 
60 Gy to 74 Gy). The planning target volume 
(PTV) was defi ned as the clinical target vol-
ume (CTV) which encompassed the prostate 
with the base of the seminal vesicles and ± 
the seminal vesicles with margins in all direc-
tions about 1.0 cm around the prostate gland 
± seminal vesicles. In each case the following 
organs at risk (OAR) were outlined: the blad-
der, rectum, colon, and femoral heads. 
Elective treatment of pelvic lymph nodes 
was included when the risk of involvement 
was higher than 15% calculated according to 
the formula proposed by Roach et al. [9] The 
elective irradiation of pelvic lymph nodes was 
based on the four-fi eld technique (the box 
technique) to a median total dose of 46 Gy, and 
then a boost to the seminal vesicles and pros-
tate gland was implemented. 
In each case the set-up and dose distribu-
tions were checked by electronic portal imag-
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ing device (EPID) and dosimetry in vivo per-
formed at the start of the treatment and then 
in each week and/or in the case of change of 
the treatment plan. 
Acute side effects including those arising 
during the irradiation course and within the 
fi rst 90 days after the completion of treatment 
were evaluated using the European Organiza-
tion for Research and Treatment of Cancer / 
Radiation Therapy Oncology Group (EORTC/
RTOG) morbidity scoring scale. The median 
time of follow-up after the treatment was 26 
months (range from 7 to 62 months). During 
the follow-up patients were followed by a radi-
ation oncologist and urologist at three-month 
intervals. No patients were lost to follow-up. 
Statistical analysis
The Kaplan-Meier method was used to esti-
mate survival curves. Comparison between 
analyzed groups was performed with the log-
rank test. In all tests a signifi cance level of 
0.05 was used. The time from the end of RT 
to the death or the last follow-up date was 
defi ned as the survival time. In overall sur-
vival (OS) analysis all causes of death were 
taken into account. In cases where the cause 
of death was unclear, the presence of clini-
cally evident prostate cancer at the time of 
death was considered death due to prostate 
cancer. For analysis of cancer, progression-
free survival (PFS), deaths due to prostate 
cancer, and regional, distant or local relapse 
of prostate cancer and/or biochemical relapse 
defi ned according to the American Society 
for Therapeutic Radiology and Oncology (AS-
TRO) defi nition were considered.  
Follow-up
For each patient the follow-up consisted of a 
medical history, digital-rectal examination, 
and PSA level (obtained prior to examina-
tion). The interval between control visits was 
3 months. During visits acute or late side ef-
fects were evaluated according the EORTC/
RTOG morbidity scale.
RESULTS
Overall survival and progression-free su-
rvival
The 5-year actuarial overall survival was 82% 
and 5-year progression-free survival rate was 
49% (Figs. 1, 2). During the follow-up 15 pa-
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tients developed disease progression (locore-
gional and/or distant and/or biochemical), two 
patients died of prostate cancer, and 5 patients 
died due to concurrent illness. The univari-
ate analysis indicated that pre-HT PSA se-
rum level > 20 ng/ml (test log rank, p= 0.03), 
and the high-risk group defi ned according to 
NCCN criteria (PSA >20 ng/ml and Gleason 
score >7) (test log-rank p= 0.01 ) were statis-
tically signifi cant factors for the risk of dis-
ease progression (Figs. 3,4,5). Other analyzed 
factors such as age, T-stage, and PSA DT were 
not indicated as prognostic factors for results 
of radiotherapy.
Side effects of therapy
Acute genitourinary (GU) symptoms included 
increased urgency, nocturia and dysuria. GU 
toxicities grade 0 and/or 1 were noted for 80% 
of patients and grade 2 in 20% of patients. The 
urinary symptoms typically appeared during 
the third week of radiotherapy treatment and 
resolved within a few weeks after the end of 
radiotherapy. Mild relief medication (anti-in-
fl ammatory) was required in 15% of patients. 
Only 10 patients were administered an alpha-1 
adrenoreceptor-blocking agent for acute uri-
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Fig. 1. 5-year overall survival
Fig. 2. Disease progression-free survival for all patients 
(Kaplan-Meier method). 
Fig. 3. Progression-free survival according to PSA DT 
Fig. 4. Progression-free survival according to combined  
risk factors (GLS and pre-HT PSA)
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Fig. 5. Disease progression-free survival according to 
pre-HT PSA 
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nary symptoms, and this treatment was very 
effective and resulted in signifi cant resolution 
of symptoms in 90% of cases. 
The most signifi cant acute adverse effects 
observed in the gastrointestinal tract (GI) 
were rectal discomfort, nausea, and mild di-
arrhoea. Generally, these side effects were 
mild to moderate (grade 1 or 2). The most 
commonly prescribed drugs for lowering the 
intensity of GI morbidities were loperamide 
and nonsteroidal anti-infl ammatory drugs 
such as ibuprofen and diclofenac. Only a few 
patients required about two weeks’ medication 
(loperamide) for diarrhoea. Acute rectal side 
effects were observed at the end of treatment 
(usually after the 4th week of irradiation mod-
erate loose-stools/diarrhoea). In general, GI 
toxicity grades 0 and 1 were observed in 75% 
of patients and grade 2 in 25% of patients. 
No acute or late GU or GI toxicities graded 
as 3 or 4 according to the RTOG/EPRTC scale 
were observed in the analyzed group of pa-
tients. The most frequent side effect observed 
from GU during the follow-up was microscop-
ic haematuria and urgency. 
The most common side effects of androgen 
ablation were “hot fl ushes”, gynecomastia, 
and loss of potency and libido, although these 
side effects were mild and not classifi ed in the 
RTOG/EORTC morbidity scale. 
DISCUSSION
Prostate cancer is one of the most important 
health problems in industrialized countries 
and the leading cause of cancer-related death. 
For the early stage of disease patients may be 
treated with surgery or radiotherapy, whose 
effi cacy is regarded as equivalent. The third 
method of treatment is hormonal therapy, 
which represents the standard treatment for 
locally advanced or metastatic prostate can-
cer [10]. In earlier clinical stages hormonal 
therapy is advocated based on individual pref-
erences of patients. 
Androgen withdrawal in groups of patients 
with prostate cancer produce subjective and/
or objective response rates in approximately 
80% of patients, but after some time the re-
sponse to androgen deprivation is diminished 
[11]. In that case the patient is classifi ed as an-
drogen independent and many different terms 
have been used to describe cancers that re-
lapse after initial hormonal ablation therapy, 
including HRPC, androgen-independent can-
cers and hormone-independent cancers [12]. 
True HRPC is commonly defi ned as at least 
two serial rises in serum PSA obtained at least 
2 weeks apart despite castrate levels of serum 
testosterone. In order to fulfi l the criteria for 
true HRPC, additional conditions such as ei-
ther antiandrogen withdrawal or one second-
ary hormonal manipulation should have been 
met. In the present work patients fulfi l only 
the fi rst part of the defi nition of HRPC and 
thus the evaluated group should be consid-
ered as androgen-independent with possible 
hormone-sensitive prostate cancer (AIPC). 
Using this defi nition a growing population 
of asymptomatic patients with a rise of PSA 
serum level but with negative re-staging for 
distant metastases can be selected. Thus, an-
drogen-independent prostate cancer is a very 
heterogeneous disease including a variety of 
different patient cohorts with signifi cant dif-
ferent median survival times. Although the 
re-staging is negative for distant metastases 
we can expect some proportion of patients for 
whom micrometastases exist. In this group of 
patients an impact of radical radiotherapy on 
survival would not be expected, but for other 
cases when cancer disease is limited to a local 
or regional stage radiotherapy may change 
the results.
It is worth adding that the subgroup of non-
metastatic HRPC patients is growing due to 
strict PSA-based evaluation of hormonal ther-
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apy and other forms such as radical prosta-
tectomy or radiotherapy. Nevertheless, for the 
non-metastatic group there is no standard ap-
proach. Treatment of non-metastatic hormone 
refractory prostate cancer is a challenge for 
both the urologist and radiation oncologist. 
According to our current understanding of 
HRPC there is no general agreement whether 
to continue testicular androgen suppression 
or not. Sustained hormonal ablation should 
still affect the population of cancer cells that 
are not hormone-resistant. On the other hand, 
an androgen withdrawal effect has been well 
documented showing a biochemical response 
after stopping hormone ablation in some pa-
tients.
The role of other methods of treatment are 
being investigated [1]. The role of radiothera-
py for patients with non-metastatic hormone-
refractory prostate cancer has not been well 
documented. The most important factor is to 
distinguish patients who are truly free from 
distant metastases from those with distant 
micrometastases. For the latter group loco-re-
gional therapy such as radiotherapy would be 
completely ineffective. According to many in-
vestigators, important parameters which may 
help to differentiate between local and distant 
relapse include: timing of PSA increase af-
ter surgery, PSA velocity, PSA doubling time 
(PSADT), pathological stage, and Gleason 
score of specimen. PSA elevations developing 
within the treatment are associated with dis-
tant recurrences [13]. It was shown that a me-
dian PSADT of 4.3 months is associated with 
distant relapse, whereas a median PSADT of 
11.7 months tends to predict local failure [14]. 
For patients with asymptomatic PSA-only pro-
gression, according to Lange et al. biochemi-
cal failure precedes clinical disease progres-
sion from 6 to 48 months [15 ].
Thus we could expect that a group of pa-
tients exists without distant or even regional 
metastases, i.e. truly free of micrometastases, 
that are classifi ed as non-metastatic HRPC, 
and such patients are good candidates for local 
therapy such as radiotherapy. The dilemma in 
considering a treatment strategy is that there 
are very scarce data concerning outcomes of 
radiotherapy in this subset of patients. More-
over, median doses of radiotherapy reported 
for such patients are lower than those typical-
ly used in prostate cancer treatment (>70Gy), 
not mentioning the recently reported possible 
advantage of using even higher doses such as 
78Gy. This probably refl ects the fact that for 
these localized but highly advanced and hor-
mone-resistant prostate cancer patients there 
is general agreement on lower doses to avoid 
unnecessary complications in the light of poor 
prognosis and more palliative-like treatment. 
It is well known that doses higher than 70Gy 
are likely to result in increased rectal wall 
toxicity. In our subset of patients the median 
dose was 70.4Gy, although there were a few 
patients treated with 60Gy for the reason giv-
en in the latter sentences.
According to Lankford et al. [6], who treat-
ed 29 patients with a median dose of 66 Gy, 
radiotherapy is highly effective in terms of lo-
cal control (61% at 4 years); however, 80% of 
patients failed with distant metastases within 
4 years. This poor outcome probably refl ects 
the fact that 79% of the patients in that study 
had disease spread to lymph nodes, which con-
fers high risk of distant spread. Therefore con-
formal high-dose treatment in that subset of 
patients should be viewed as solely palliative 
intervention. In contrast, in our study patients 
with lymph node involvement were excluded 
and this approach resulted in relatively good 
outcome of 5-year PFS and OS at the level of 
49% and 82%, respectively. Comparable re-
sults were recently published by Akimoto et 
al., with 5-year clinical relapse-free and over-
all survival of 56% and 87%, respectively [7].
They also referred to their study only patients 
who had no signs of lymph node metastases 
as evaluated by CT. However, in their study a 
hypofractionated regimen with fraction dose 
of 3 Gy given three times weekly was imple-
mented. Therefore, having in mind the disput-
able value of  ?/ß  ratio in adenocarcinoma of 
the prostate, it is diffi cult to directly compare 
these studies [16]. 
Another key issue is the infl uence of pos-
sible radioresistance of prostate cancer cells 
in the phase of androgen independence. Many 
studies have focused on the deregulation of 
apoptosis in the development of androgen-
independent disease. High levels of bcl-2 ex-
pression are seen with greater frequency as 
CaP progresses, and a mechanism by which 
bcl-2 induces its anti-apoptotic effect may be 
the regulation of microtubule integrity. The 
fact that the most active chemotherapeutics 
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in HRPC work by inhibiting microtubule for-
mation suggests that these fi ndings may be 
clinically relevant. The tumour suppressor 
gene p53 is more frequently mutated in andro-
gen-independent CaP. Over-expression of bcl-
2 and p53 in prostatectomy specimens have 
been shown to predict an aggressive clinical 
course.
Our analysis indicated very poor radiother-
apy results in the subgroup classifi ed as non-
metastatic ARPC patients with high-risk fac-
tors (pre-HT PSA >20 ng/ml + Gleason score 
> 7). On the other hand, radiotherapy could 
be a valuable method of treatment for patients 
with lower risk of distant failure classifi ed as 
pre-HT PSA < 20 ng/ml, Gleason score < 8.     
Patients with diagnosis of HRPC present a 
very heterogeneous population, and therefore 
it has been proposed to sub-categorize them 
into two subgroups depending on presence or 
absence of distant metastases. While the for-
mer subgroup has been typically treated with 
palliative intention, for the latter apparently 
there is no standard approach. 
In the analyzed group of patients only 43 out 
of 424 patients received ADT as sole treatment. 
Such a strategy of treatment was advocated 
by leading urologists, who started hormonal 
therapy very early after having obtained the 
diagnosis of prostate cancer (e.g. T3). During 
the hormonal therapy, biochemical failure oc-
curred. In such cases 80% of patients changed 
their decision and chose RT. From this group 
after re-staging distant metastases were indi-
cated in 10% of patients who were not included 
in radiotherapy radical treatment.
Generally, the data from the literature in-
dicate that combined treatment (hormonal 
therapy plus radiotherapy) may lead to prolon-
gation of overall survival in a more advanced 
stage of disease [17 EUA]. An example of com-
bined treatment was the trial study conducted 
by RTOG (RTOG 9202): neoadjuvant andro-
gen ablation was introduced 2 months prior 
to irradiation and then was continued during 
radiotherapy and for 2 years after termination 
of irradiation. In a group of patients treated 
with hormonal therapy and radiotherapy the 
5-year overall survival rate was 80% vs. 69% 
in patients without additional hormone thera-
py [18]. Another well documented trial study, 
which showed a therapeutic benefi t, was car-
ried out by Bolla et al. [19], who confi rmed that 
combined treatment resulted in an increase of 
5-year survival from 62% to 79% (p= 0.001).
In our study combination of androgen de-
privation therapy and RT was based on dif-
ferent rules and indication that a typical 
combined treatment strategy exists. Thus, it 
is impossible to answer the question of what 
is the relationship between androgen depriva-
tion therapy and RT. 
One of the most important issues of treat-
ment of patients with diagnosis of HRPC apart 
from prolongation of survival is avoiding sig-
nifi cant side effects of therapy which could in-
fl uence the quality of life of treated patients. 
From this point of view during the course of 
radiotherapy and follow-up we did not observe 
any signifi cant side effects scored as grade III 
according to the RTOG/EORTC classifi cation. 
Treatment of non-metastatic HRPC pa-
tients is a challenge for both urologists and ra-
diotherapists. Implementation of radiotherapy 
in case of distant metastases or in very high 
risk of distant failure (micrometastases) pro-
duces morbidity and is connected with high 
cost of treatment which is represented by di-
rect and indirect costs. In such cases radio-
therapy constitutes a costly form of palliative 
treatment. Another aspect of strategy of treat-
ment of patients with non-metastatic HRPC 
concerns the subgroup of patients who are po-
tential candidates for cure or prolongation of 
survival due to application of radiotherapy but 
did not receive such treatment. Thus, the key 
for the group of patients with non-metastatic 
HRPC is to fi nd the subgroup which will be 
candidates to obtain therapeutic gain. 
The role of three-dimensional conformal ra-
diotherapy (3D-CRT) for this subgroup, which 
comprises a signifi cant proportion of prostate 
cancer patients, has not been well documented 
in the literature. 
CONCLUSIONS
Three-dimensional conformal radiotherapy for 
patients with non-metastatic ARPC is a valu-
able method of treatment in terms of progres-
sion-free survival provided to the subgroup 
of patients with pre-HT PSA<20 ng/ml and 
Gleason score < 8. For patients classifi ed as 
high risk according to NCCN criteria, 3D-CRT 
seems to be an ineffective treatment due to the 
observed high incidence of distant failure and 
should be viewed as a costly and sophisticated 
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yet ineffective intervention. For this subgroup 
a systemic modality of treatment such as che-
motherapy or biological manipulation should 
be considered.
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